Brokerages Anticipate Galectin Therapeutics Inc. (NASDAQ:GALT) to Announce -$0.19 Earnings Per Share

Equities analysts predict that Galectin Therapeutics Inc. (NASDAQ:GALTGet Rating) will announce earnings per share of ($0.19) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Galectin Therapeutics’ earnings. Galectin Therapeutics posted earnings per share of ($0.15) in the same quarter last year, which indicates a negative year-over-year growth rate of 26.7%. The business is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Galectin Therapeutics will report full year earnings of ($0.75) per share for the current fiscal year. For the next financial year, analysts anticipate that the company will post earnings of ($0.68) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Galectin Therapeutics.

Galectin Therapeutics (NASDAQ:GALTGet Rating) last issued its quarterly earnings results on Monday, May 16th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02).

Several research analysts have recently issued reports on the company. HC Wainwright reduced their price objective on Galectin Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, May 17th. assumed coverage on Galectin Therapeutics in a research note on Tuesday, May 17th. They issued a “sell” rating for the company.

Several large investors have recently made changes to their positions in GALT. Centaurus Financial Inc. purchased a new position in Galectin Therapeutics during the first quarter valued at approximately $34,000. Virtu Financial LLC acquired a new stake in Galectin Therapeutics in the fourth quarter valued at approximately $37,000. Commonwealth Equity Services LLC grew its holdings in Galectin Therapeutics by 59.2% in the first quarter. Commonwealth Equity Services LLC now owns 26,902 shares of the company’s stock valued at $43,000 after purchasing an additional 10,000 shares during the period. Raymond James & Associates acquired a new stake in Galectin Therapeutics in the third quarter valued at approximately $51,000. Finally, Benjamin F. Edwards & Company Inc. grew its holdings in Galectin Therapeutics by 25.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 29,615 shares of the company’s stock valued at $61,000 after purchasing an additional 6,015 shares during the period. Hedge funds and other institutional investors own 12.35% of the company’s stock.

NASDAQ GALT traded down $0.13 during trading on Tuesday, hitting $1.19. The company’s stock had a trading volume of 97,575 shares, compared to its average volume of 111,391. Galectin Therapeutics has a fifty-two week low of $1.19 and a fifty-two week high of $4.40. The company has a market cap of $70.67 million, a PE ratio of -2.05 and a beta of 1.64. The company has a debt-to-equity ratio of 79.37, a current ratio of 3.51 and a quick ratio of 4.63. The business’s 50 day simple moving average is $1.58 and its 200-day simple moving average is $1.99.

Galectin Therapeutics Company Profile (Get Rating)

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Featured Stories

Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with's FREE daily email newsletter.